Society guidelines, US treatment algorithm, and NIH consensus: Similarities and differences in management of hepatitis B

被引：0
作者：
Han S.-H.B. [1 ]
Yang J.C. [1 ]
机构：
[1] Pfleger Liver Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095
来源：
Current Hepatitis Reports | 2009年 / 8卷 / 4期
基金：
美国国家卫生研究院;
关键词：
Adefovir; Tenofovir Disoproxil Fumarate; Entecavir; Telbivudine;
D O I：
10.1007/s11901-009-0023-9
中图分类号：
学科分类号：
摘要：
Currently, five published guidelines focus on the treatment of chronic hepatitis B endorsed by the Indian Association for the Study of the Liver (2002), the American Association for the Study of Liver Diseases (2007), the Asian Pacific Association for the Study of the Liver (updated 2008), the European Association for the Study of the Liver (updated 2009), and the National Institutes of Health consensus committee (2009). In addition, an algorithm developed by a panel of US hepatologists regarding the management of chronic hepatitis B was updated in 2008. The guidelines are based on published evidence, and the US algorithm includes expert opinion when available data were lacking. In this review, we discuss the important similarities and differences among the different publications regarding threshold for treatment, choice of initial agents for therapy, management of drug-resistant hepatitis B, and treatment of patients with cirrhosis. © 2009 Springer Science+Business Media, LLC.
引用
收藏
页码：161 / 168
页数：7
相关论文
共 38 条
  • [1] Lee W.M., Hepatitis B virus infection, New England Journal of Medicine, 337, 24, pp. 1733-1745, (1997)
  • [2] McQuillan G.M., Coleman P.J., Kruszon-Moran D., Et al., Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994, Am J Public Health, 89, pp. 14-18, (1999)
  • [3] Sarin S.K., Summary and recommendations of single theme conferences on hepatitis B and C: Indian association for study of the liver (INASL), Journal of Gastroenterology and Hepatology, 17, SUPPL. 3, (2002)
  • [4] Lok A.S.F., McMahon B.J., Chronic hepatitis B, Hepatology, 45, 2, pp. 507-539, (2007)
  • [5] Liaw Y.F., Suh D.J., Omata M., APASL Guidelines for HBV Management (Provisional), (2008)
  • [6] Easl clinical practice guidelines: Management of chronic hepatitis B, J Hepatol, 50, pp. 227-242, (2009)
  • [7] Sorrell M.F., Belongia E.A., Costa J., Et al., National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B, Ann Intern Med, 150, pp. 104-110, (2009)
  • [8] Keeffe E.B., Dieterich D.T., Han S.H., Et al., A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update, Clin Gastroenterol Hepatol, 6, pp. 1315-1341, (2008)
  • [9] Perrillo R.P., Lai C.-L., Liaw Y.-F., Dienstag J.L., Schiff E.R., Schalm S.W., Heathcote E.Jenny, Brown N.A., Atkins M., Woessner M., Gardner S.D., Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B, Hepatology, 36, 1, pp. 186-194, (2002)
  • [10] Lok A.S.F., Wu P.C., Lai C.L., Et al., A controlled trial of interferon with or without prednisone priming for chronic hepatitis B, Gastroenterology, 102, pp. 2091-2097, (1992)
1234